DC-S239

DC-S239

D656006-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC 50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1 , DOT1L , EZH2 , NSD1, SETD8 and G9a. DC-S239 has anticancer activity In Vitro DC-S239 inhibits DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a by less than 45%, while it inhibits SET7 by 90% at concentrations of 100 μM. DC-S239 (0-100 μM, 120 h) can inhibit the proliferation of MCF7, HL60 and MV4-11 cells in a dose-dependent manner but no significant effect on the activity of HCT116 and DHL4 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MCF7, HL60, DHL4, MV4-11 and HCT116 cell lines Concentration: 0-100 μM Incubation Time: 120 h Result: Inhibited MCF7 and HL60 with the IC 50 values of 10.93 μM and 16.43 μM, respectively. IC50& Target:IC50: 4.59 μM (SET7)

DC-S239 是一种选择性组蛋白甲基转移酶 SET7 抑制剂，其 IC 50 值为 4.59 μM。DC-S239 还对 DNMT1、DOT1L、EZH2、NSD1、SETD8 和 G9a 具有选择性。DC-S239 具有抗癌活性。

303141-21-1(DMSO)

C15H15N3O5S

349.36 g/mol

O=C(OCC)C1=C(SC(C(NC2=CC=CC([N+]([O-])=O)=C2)=O)=C1C)N